



## **EGF THERAMED HEALTH CORP. PROVIDES CLARIFICATION ON NEWS RELEASE**

**Vancouver, B.C., April 30, 2020** – EGF THERAMED HEALTH CORP. (CSE: TMED, OTCQB: EVAHF) (the “**Company**”) further to the news release dated April 29, 2020, the company would like to clarify that all securities issued in the second tranche offering are subject to a hold period expiring on August 30, 2020.

The Company would also like to clarify that the grant of 175,000 stock options to certain directors of the Company, will be exercisable at \$1.00 for twenty-four months from the date of issuance.

For more information please contact:

### **EGF THERAMED HEALTH CORP.**

Contact: David Bentil, CEO

Email [theramedhealthcorp@gmail.com](mailto:theramedhealthcorp@gmail.com)

Telephone: (778) 559-3939

Website <http://www.theramedhealthcorp.com>

CSE Micro-site: <http://thecse.com/en/listings/technology/Theramed-Health-Corporation>

US OTC Markets (OTCQB): <http://www.otcmarkets.com/stock/EVAHF/news>

### **About EGF Theramed Health Corp.**

EGF Theramed Health Corp. is a consumer technology company engaged in the provision of biomedical online services for monitoring and treating common health problems. The Company, through its subsidiaries, has assets and technologies used in the extraction and purification of botanical extracts and the creation of extract formulations, as well as medical monitoring device technology. The Company is seeking to be the first company to offer a complete quality assured vertically integrated “Natural Products and Herbal Health System” for monitoring, dosing, and recording the effects of natural products on the cardiovascular system.

### **DISCLAIMERS**

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect the use of funds raised in the private placement, option grant, its research into psilocybin and its mission to become the first company to offer a “Natural Products and Herbal Health System” for monitoring, dosing, and recording the effects of natural products on the cardiovascular system. The Company provides forward-looking statements for the purpose of

conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited to those identified and reported in the Company's public filings under the Company's SEDAR profile at [www.sedar.com](http://www.sedar.com). Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "**U.S. Securities Act**"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.